Wakamoto Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wakamoto Pharmaceutical Co., Ltd. with three other
companies in this sector in JAPAN :
Biofermin Pharmaceutical Company Limited
sales of 11.92 billion Japanese Yen [US$114.36 million]
of which 63%
was New BioferminS),
I'rom Group Co Ltd
(10.59 billion Japanese Yen [US$101.59 million]
of which 59%
was Smo Business), and
Taiko Pharmaceutical Company., Limited
(14.97 billion Japanese Yen [US$143.53 million]
of which 62%
was Infection Control).
Wakamoto Pharmaceutical Co., Ltd. reported sales of ¥10.92 billion (US$104.69 million)
March of 2020.
a very small
increase of 1.6%
versus 2019, when the company's sales were ¥10.74 billion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Wakamoto Pharmaceutical Co., Ltd. had sales
of ¥10.62 billion.
Sales of Healthcare Bussiness saw an increase
that was more than double the company's growth rate: sales were up
14.4% in 2020, from
¥3.07 billion to ¥3.52 billion.
Not all segments of Wakamoto Pharmaceutical Co., Ltd. experienced an increase in sales in 2020:
sales of Medical Pharmaceutical Products fell 3.9% to ¥6.57 billion.
Wakamoto Pharmaceutical Co., Ltd. also experienced decreases in sales in
International Bussiness (down 0.8% to ¥639.85 million)